Therapeutic effect of a TM4SF5-specific peptide vaccine against colon cancer in a mouse model
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Molecular-targeted therapy has gained attention because of itshigh efficacy and weak side effects. Previously, we confirmedthat transmembrane 4 superfamily member 5 protein (TM4SF5)can serve as a molecular target to prevent or treat hepatocellularcarcinoma (HCC). We recently extended the application of thepeptide vaccine, composed of CpG-DNA, liposome complex,and TM4SF5 peptide, to prevent colon cancer in a mousemodel. Here, we first implanted mice with mouse colon cancercells and then checked therapeutic effects of the vaccine againsttumor growth. Immunization with the peptide vaccine resultedin robust production of TM4SF5-specific antibodies, alleviatedtumor growth, and reduced survival rate of the tumor-bearingmice. We also found that serum levels of VEGF were markedlyreduced in the mice immunized with the peptide vaccine. Therefore, we suggest that the TM4SF5-specific peptide vaccinehas a therapeutic effect against colon cancer in a mouse model.
Abstract
Molecular-targeted therapy has gained attention because of itshigh efficacy and weak side effects. Previously, we confirmedthat transmembrane 4 superfamily member 5 protein (TM4SF5)can serve as a molecular target to prevent or treat hepatocellularcarcinoma (HCC). We recently extended the application of thepeptide vaccine, composed of CpG-DNA, liposome complex,and TM4SF5 peptide, to prevent colon cancer in a mousemodel. Here, we first implanted mice with mouse colon cancercells and then checked therapeutic effects of the vaccine againsttumor growth. Immunization with the peptide vaccine resultedin robust production of TM4SF5-specific antibodies, alleviatedtumor growth, and reduced survival rate of the tumor-bearingmice. We also found that serum levels of VEGF were markedlyreduced in the mice immunized with the peptide vaccine. Therefore, we suggest that the TM4SF5-specific peptide vaccinehas a therapeutic effect against colon cancer in a mouse model.
참고문헌 (30)
- Abbas, A., "Cellular and molecular immunology", pp.351~373 (2010), Saunders, Elsevier
- Aly, H. A., "Cancer therapy and vaccination", J. Immunol. Methods, 382, pp.1~23 (2012)
- Montomoli, E., "Current adjuvants and new perspectives in vaccine formulation", Expert. Rev. Vaccines, 10, pp.1053~1061 (2011)
- Krieg, A. M., "CpG motifs in bacterial DNA and their immune effects", Annu. Rev. Immunol, 20, pp.709~760 (2002)
- Klinman, D. M., "Use of CpG oligodeoxynucleotides as immune adjuvants", Immunol. Rev, 199, pp.201~216 (2004)
- Bode, C., "CpG DNA as a vaccine adjuvant", Expert. Rev. Vaccines, 10, pp.499~511 (2011)
- Davis, H. L., "CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen", J. Immunol, 160, pp.870~876 (1998)
- Carson, D. A., "Oligonucleotide adjuvants for T helper 1 (Th1)-specific vaccination", J. Exp. Med, 186, pp.1621~1622 (1997)
- Chu, R. S., "CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity", J. Exp. Med, 186, pp.1623~1631 (1997)
- Lee, K. W., "Immunostimulatory oligodeoxynucleotide isolated from genome wide screening of Mycobacterium bovis chromosomal DNA", Mol. Immunol, 43, pp.2107~2118 (2006)
- 김동범, "Adjuvant effect of liposome-encapsulated natural phosphodiester CpG-DNA", BMB Reports, 44(11), pp.758~763 (2011), 생화학분자생물학회
- Kim, D., "Production of antibodies with peptide- CpG-DNA-liposome complex without carriers", BMC Immunol, 12, pp.29~ (2011)
- 김동범, "Activation of Toll-like receptor 9 and production of epitope specific antibody by liposome-encapsulated CpG-DNA", BMB Reports, 44(9), pp.607~612 (2011), 생화학분자생물학회
- Lee, Y, "Production of epitope-specific antibodies using peptide-CpG-ODN-liposome complex without carriers and their application as a cancer vaccine in mice", Oncoimmunology, 1, pp.1215~1217 (2012)
- Llovet, J. M., "Molecular targeted therapies in hepatocellular carcinoma", Hepatology, 48, pp.1312~1327 (2008)
- Tanaka, S., "Molecular targeted therapy for hepatocellular carcinoma in the current and potential next strategies", J. Gastroenterol, 46, pp.289~296 (2011)
- Muller-Pillasch, F., "Identification of a new tumour-associated antigen TM4SF5 and its expression in human cancer", Gene, 208, pp.25~30 (1998)
- Lee, S. A., "Tetraspanin TM4SF5 mediates loss of contact inhibition through epithelial- mesenchymal transition in human hepatocarcinoma", J. Clin. Invest, 118, pp.1354~1366 (2008)
- Lee, S. A., "Blockade of four-transmembrane L6 family member 5 (TM4SF5)-mediated tumorigenicity in hepatocytes by a synthetic chalcone derivative", Hepatology, 49, pp.1316~1325 (2009)
- Kwon, S., "Prevention and therapy of hepatocellular carcinoma by vaccination with TM4SF5 epitope-CpG-DNA-liposome complex without carriers", PLoS One, 7, pp.e33121~ (2012)
- Kwon, S., "Induction of immunological memory response by vaccination with TM4SF5 epitope-CpG-DNA-liposome complex in a mouse hepatocellular carcinoma model", Oncol. Rep, 29, pp.735~740 (2013)
- Kwon, S., "Prophylactic effect of a peptide vaccine targeting TM4SF5 against colon cancer in a mouse model", Biochem. Biophys. Res. Commun, 435, pp.134~139 (2013)
- Schreiber, T. H., "Tumor immunogenicity and responsiveness to cancer vaccine therapy: the state of the art. Semin", Immunol, 22, pp.105~112 (2010)
- Yoshiji, H., "The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor", Clin. Cancer Res, 7, pp.1073~1078 (2001)
- Choi, K. S., "Hypoxia-induced angiogenesis during carcinogenesis", J. Biochem. Mol. Biol, 36, pp.120~127 (2003)
- Mercurio, A. M., "Non-angiogenic functions of VEGF in breast cancer", J. Mammary Gland Biol. Neoplasia, 10, pp.283~290 (2005)
- Choi, S., "Cooperation between integrin alpha5 and tetraspan TM4SF5 regulates VEGF-mediated angiogenic activity", Blood, 113, pp.1845~1855 (2009)
- Yoshiji, H., "Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis", Cancer Res, 59, pp.4413~4418 (1999)
- 김남훈, "Antiproliferative effect of gold(I) compound auranofin through inhibition of STAT3 and telomerase activity in MDA-MB 231 human breast cancer cells", BMB Reports, 46(1), pp.59~64 (2013), 생화학분자생물학회
- Caihong Zhou, "Overexpression of TTRAP inhibits cell growth and induces apoptosis in osteosarcoma cells", BMB Reports, 46(2), pp.113~118 (2013), 생화학분자생물학회